-
Sector Analysis
Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Anal Cancer Marketed and Pipeline Drugs Report Overview Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition....
-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Non-Small Cell Lung Cancer Drug Details:E-602 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)Drug Details:...
-
Company Insights
Innovation and Patenting activity of Catalyst Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Catalyst Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Report Overview Lennox-Gastaut Syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Affected children experience several different types of seizures, such as atonic, tonic, and atypical absence seizures. Children with LGS may also develop cognitive dysfunction, delays in reaching developmental milestones, and behavioral problems. Key Mechanism of Action (Marketed) ·       Receptor Agonists ·       Ion Channel Blockers ·       Enzyme Inhibitors ·       Receptor Antagonists ·       Transporter Inhibitors...
-
Sector Analysis
Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Dravet Syndrome (DS) Marketed and Pipeline Drugs Report Overview Dravet syndrome is also known as severe myoclonic epilepsy of infancy (SMEI). It is a rare and severe form of epilepsy that typically begins in the first year of life. The exact cause of Dravet syndrome is usually genetic. However, seizures in affected individuals can be triggered by various factors including fever, infections, and sometimes vaccinations. These triggers can lead to prolonged and potentially life-threatening seizures known as status epilepticus. Genetic...
-
Sector Analysis
Acute Renal Failure (ARF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Renal Failure (ARF) Marketed and Pipeline Drugs Report Overview Acute Renal Failure (ARF) or Acute Kidney Injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. ARF causes a buildup of waste products in the blood and makes it hard for the kidneys to keep the right balance of fluid in your body. ARF can also affect other organs, such as the brain, heart, and lungs. This...
-
Sector Analysis
Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Crohn’s Disease Market Report Overview The Crohn’s disease market size across the 8MM was $9.5 billion in 2022. The market will achieve a CAGR of more than 4% during 2022-2032 because of the approval and launch of 15 pipeline, generic, and biosimilar therapies. Crohn’s Disease Market Outlook, 2022-2032 ($ Billion) Buy the Full Report to Know More About the Crohn’s Disease Market Forecast Download a Free Report Sample The Crohn’s disease market research report offers a comprehensive insight into the...